Clinical Trial Update: Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing ranibizumab to photodynamic therapy for presumed ocular histoplasmosis, with current status listed as unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Histoplasmosis

Drugs mentioned

• Photodynamic Therapy
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Barnes Retina Institute | Conditions: Presumed Ocular Histoplasmosis (POHS) | Phase 2 | Status: UNKNOWN